Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.1 HKD | -0.15% | -11.08% | -30.55% |
May. 23 | Keymed's Anti-Rhinosinusitis Drug Set For Priority Review in China | MT |
Apr. 30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-30.55% | 1.21B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.22% | 21.78B | |
-9.14% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed's Rhinosinusitis Treatment Achieves Primary Endpoints; Shares Rise 5%